| dbo:abstract |
Clovis Oncology is an American pharmaceutical company which mainly markets products for treatment in oncology. Clovis was founded in 2009 and is headquartered in Boulder, Colorado. The company is a publicly traded company on NASDAQ under the symbol CLVS and is in the NASDAQ Biotechnology Index with several products in its product pipeline. As of December 31, 2017, the company was not profitable and had incurred losses in each year since its inception in April 2009. (en) |
| dbo:industry |
dbr:Pharmaceutical_industry |
| dbo:locationCity |
dbr:Boulder,_Colorado dbr:Colorado |
| dbo:numberOfEmployees |
429 (xsd:nonNegativeInteger) |
| dbo:revenue |
1.65E8 |
| dbo:thumbnail |
wiki-commons:Special:FilePath/Clovis_Oncology_logo.svg?width=300 |
| dbo:type |
dbr:Public_company |
| dbo:wikiPageExternalLink |
https://clovisoncology.com/ |
| dbo:wikiPageID |
48994417 (xsd:integer) |
| dbo:wikiPageLength |
9169 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1070946733 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:Rucaparib dbr:Non-small_cell_lung_cancer dbr:Boulder,_Colorado dbr:Pharmaceutical_company dbr:Public_company dbr:Rociletinib dbr:Colorado dbr:Russell_2000_Index dbr:NASDAQ_Biotechnology_Index dbr:Clovis_culture dbr:NASDAQ dbr:Somatic_evolution_in_cancer dbr:Pharmaceutical_industry dbr:BRCA_mutation dbr:U.S._Securities_and_Exchange_Commission dbr:Food_and_Drug_Administration dbr:Osimertinib dbr:Germline_mutation dbr:Lucitanib dbc:Pharmaceutical_companies_of_the_United_States dbr:Accelerated_approval_(FDA) dbr:FGFR1 dbr:FGFR2 dbr:Oncology dbr:Ovarian_cancer dbr:PARP_inhibitor dbr:Chemotherapies dbr:VEGFR_inhibitor |
| dbp:founded |
in Boulder, Colorado (en) |
| dbp:founder |
Patrick Mahaffy (en) |
| dbp:hqLocationCity |
Boulder, Colorado (en) |
| dbp:hqLocationCountry |
U.S. (en) |
| dbp:industry |
dbr:Pharmaceutical_industry |
| dbp:logo |
Clovis Oncology logo.svg (en) |
| dbp:logoSize |
270 (xsd:integer) |
| dbp:name |
Clovis Oncology (en) |
| dbp:numEmployees |
429 (xsd:integer) |
| dbp:revenue |
1.65E8 |
| dbp:tradedAs |
dbr:Russell_2000_Index NASDAQ:CLVS (en) |
| dbp:type |
dbr:Public_company |
| dbp:website |
https://clovisoncology.com/ |
| dbp:wikiPageUsesTemplate |
dbt:Authority_control dbt:Increase dbt:Infobox_company dbt:Reflist dbt:Short_description dbt:Start_date_and_age dbt:Use_American_English dbt:Use_mdy_dates |
| dcterms:subject |
dbc:Pharmaceutical_companies_of_the_United_States |
| gold:hypernym |
dbr:Company |
| rdf:type |
owl:Thing dbo:Company schema:Organization dul:Agent dul:SocialPerson dbo:Agent wikidata:Q24229398 wikidata:Q43229 wikidata:Q4830453 dbo:Organisation |
| rdfs:comment |
Clovis Oncology is an American pharmaceutical company which mainly markets products for treatment in oncology. Clovis was founded in 2009 and is headquartered in Boulder, Colorado. The company is a publicly traded company on NASDAQ under the symbol CLVS and is in the NASDAQ Biotechnology Index with several products in its product pipeline. As of December 31, 2017, the company was not profitable and had incurred losses in each year since its inception in April 2009. (en) |
| rdfs:label |
Clovis Oncology (en) |
| owl:sameAs |
yago-res:Clovis Oncology yago-res:Clovis Oncology yago-res:Clovis Oncology wikidata:Clovis Oncology https://global.dbpedia.org/id/2FD9a |
| skos:closeMatch |
http://www.grid.ac/institutes/grid.476183.f |
| prov:wasDerivedFrom |
wikipedia-en:Clovis_Oncology?oldid=1070946733&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/Clovis_Oncology_logo.svg |
| foaf:homepage |
https://clovisoncology.com/ |
| foaf:isPrimaryTopicOf |
wikipedia-en:Clovis_Oncology |
| foaf:name |
Clovis Oncology (en) |
| is dbo:wikiPageDisambiguates of |
dbr:Clovis |
| is dbo:wikiPageWikiLink of |
dbr:Rucaparib dbr:List_of_drugs_granted_breakthrough_therapy_designation dbr:List_of_pharmaceutical_companies dbr:Rociletinib dbr:Clovis dbr:Lucitanib dbr:Abingworth_(company) dbr:New_Enterprise_Associates |
| is foaf:primaryTopic of |
wikipedia-en:Clovis_Oncology |
